多克隆高免疫球蛋白：一种经过验证的被动免疫治疗和预防平台，可用于应对现有和新出现的疾病。
Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases.
机构信息
Therapeutics Business Unit, Emergent BioSolutions Incorporated, Winnipeg, MB, Canada.
Department of Immunology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
出版信息
Hum Vaccin Immunother. 2022 Apr 29;18(2):1886560. doi: 10.1080/21645515.2021.1886560. Epub 2021 May 19.
Abstract
Passive immunization with polyclonal hyper immunoglobulin (HIG) therapy represents a proven strategy by transferring immunoglobulins to patients to confer immediate protection against a range of pathogens including infectious agents and toxins. Distinct from active immunization, the protection is passive and the immunoglobulins will clear from the system; therefore, administration of an effective dose must be maintained for prophylaxis or treatment until a natural adaptive immune response is mounted or the pathogen/agent is cleared. The current review provides an overview of this technology, key considerations to address different pathogens, and suggested improvements. The review will reflect on key learnings from development of HIGs in the response to public health threats due to Zika, influenza, and severe acute respiratory syndrome coronavirus 2.
摘要
被动免疫接种多克隆高免疫球蛋白（HIG）治疗代表了一种通过将免疫球蛋白转移给患者来提供针对多种病原体（包括传染性病原体和毒素）的即时保护的成熟策略。与主动免疫不同，这种保护是被动的，免疫球蛋白将从系统中清除；因此，必须维持有效剂量的给药以进行预防或治疗，直到自然适应性免疫反应建立或病原体/抗原被清除。本综述概述了该技术，解决不同病原体的关键注意事项以及提出的改进建议。本综述将从应对寨卡病毒、流感和严重急性呼吸综合征冠状病毒 2 等公共卫生威胁时开发 HIG 的经验中吸取关键教训。
相似文献
1
Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases.多克隆高免疫球蛋白：一种经过验证的被动免疫治疗和预防平台，可用于应对现有和新出现的疾病。
Hum Vaccin Immunother. 2022 Apr 29;18(2):1886560. doi: 10.1080/21645515.2021.1886560. Epub 2021 May 19.
2
Immunization against severe acute respiratory syndrome Coronavirus 2: an overview.针对严重急性呼吸综合征冠状病毒 2 的免疫接种：概述。
Afr Health Sci. 2021 Dec;21(4):1574-1583. doi: 10.4314/ahs.v21i4.11.
3
Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2.生产和质量保证人类多克隆抗 SARS-CoV-2 高免免疫球蛋白。
Transfus Med Rev. 2022 Jul;36(3):125-132. doi: 10.1016/j.tmrv.2022.06.001. Epub 2022 Jun 9.
4
Zika Virus-Specific IgY Results Are Therapeutic Following a Lethal Zika Virus Challenge without Inducing Antibody-Dependent Enhancement.寨卡病毒特异性 IgY 结果在致命寨卡病毒挑战后具有治疗作用，而不会引起抗体依赖性增强。
Viruses. 2019 Mar 26;11(3):301. doi: 10.3390/v11030301.
5
Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis.经鼻给药的超浓缩抗呼吸道合胞病毒免疫球蛋白：一种有前景的呼吸道合胞病毒预防方法。
Front Immunol. 2021 Jun 7;12:683902. doi: 10.3389/fimmu.2021.683902. eCollection 2021.
6
Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.《关于 2019 年冠状病毒病的被动免疫：包括恢复期血浆在内的治疗方面的述评》
Semin Thromb Hemost. 2020 Oct;46(7):796-803. doi: 10.1055/s-0040-1712157. Epub 2020 Jun 11.
7
Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role.人免疫球蛋白作为抗感染治疗的应用：迄今为止的经验及其可能再次出现的作用。
Expert Rev Anti Infect Ther. 2017 Jun;15(6):585-604. doi: 10.1080/14787210.2017.1328278. Epub 2017 May 15.
8
SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.SARS-CoV-2 中和在恢复期血浆和商业的血浆衍生免疫球蛋白产品中。
BioDrugs. 2022 Jan;36(1):41-53. doi: 10.1007/s40259-021-00511-9. Epub 2021 Nov 29.
9
Immune-Based Therapy for COVID-19.基于免疫的COVID-19治疗方法。
Adv Exp Med Biol. 2021;1318:449-468. doi: 10.1007/978-3-030-63761-3_26.
10
Chicken IgY Antibodies Provide Mucosal Barrier against SARS-CoV-2 Virus and Other Pathogens.鸡卵黄免疫球蛋白抗体为黏膜提供针对 SARS-CoV-2 病毒和其他病原体的屏障。
Isr Med Assoc J. 2021 Apr;23(4):208-211.
引用本文的文献
1
Current status of next-generation vaccines against mpox virus: a scoping review.抗猴痘病毒的下一代疫苗的现状：一项范围综述
Front Pharmacol. 2025 Apr 28;16:1533533. doi: 10.3389/fphar.2025.1533533. eCollection 2025.
2
Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase.同时靶向流感病毒血凝素和神经氨酸酶的具有广泛保护作用的双特异性抗体。
mBio. 2024 Jul 17;15(7):e0108524. doi: 10.1128/mbio.01085-24. Epub 2024 Jun 20.
3
SIR+ models: accounting for interaction-dependent disease susceptibility in the planning of public health interventions.SIR 模型：在公共卫生干预规划中考虑与相互作用相关的疾病易感性。
Sci Rep. 2024 Jun 5;14(1):12908. doi: 10.1038/s41598-024-63008-9.
4
Comparison of neutralization potency across passive immunotherapy approaches as potential treatments for emerging infectious diseases.作为新兴传染病潜在治疗方法的被动免疫疗法中中和效力的比较。
Heliyon. 2023 Dec 16;10(1):e23478. doi: 10.1016/j.heliyon.2023.e23478. eCollection 2024 Jan 15.
5
A lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection.一种针对 SARS-CoV-2 感染的广谱中和抗体的肺选择性 mRNA 递呈。
Nat Commun. 2023 Dec 5;14(1):8042. doi: 10.1038/s41467-023-43798-8.
6
Equine Polyclonal Antibodies Prevent Acute Chikungunya Virus Infection in Mice.马多克隆抗体可预防小鼠感染急性基孔肯雅病毒。
Viruses. 2023 Jun 29;15(7):1479. doi: 10.3390/v15071479.
7
Passive Transfer of Animal-Derived Polyclonal Hyperimmune Antibodies Provides Protection of Mice from Lethal Lassa Virus Infection.动物源多克隆高免抗体的被动转移可保护小鼠免受致死性拉沙病毒感染。
Viruses. 2023 Jun 26;15(7):1436. doi: 10.3390/v15071436.
8
Prevention of Congenital Cytomegalovirus Infection: Review and Case Series of Valaciclovir versus Hyperimmune Globulin Therapy.预防先天性巨细胞病毒感染：伐昔洛韦与免疫球蛋白治疗的综述和病例系列。
Viruses. 2023 Jun 15;15(6):1376. doi: 10.3390/v15061376.
9
Enhancing the therapeutic activity of hyperimmune IgG against chikungunya virus using FcγRIIIa affinity chromatography.利用 FcγRIIIa 亲和层析技术增强抗基孔肯雅病毒的高免疫 IgG 的治疗活性。
Front Immunol. 2023 May 12;14:1153108. doi: 10.3389/fimmu.2023.1153108. eCollection 2023.
10
Neonatal sepsis and transient immunodeficiency: Potential for novel immunoglobulin therapies?新生儿败血症和短暂性免疫缺陷：新型免疫球蛋白治疗的潜力？
Front Immunol. 2022 Oct 18;13:1016877. doi: 10.3389/fimmu.2022.1016877. eCollection 2022.
本文引用的文献
1
Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein.针对 SARS-CoV-2 刺突蛋白的生物医学干预措施迅速进化逃逸的风险。
PLoS One. 2021 Apr 28;16(4):e0250780. doi: 10.1371/journal.pone.0250780. eCollection 2021.
2
A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential.一种具有吸入给药潜力的强效抗SARS-CoV-2中和纳米抗体。
MedComm (2020). 2021 Mar;2(1):101-113. doi: 10.1002/mco2.60. Epub 2021 Mar 4.
3
Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies.结构基础：人源强效中和抗体对 SARS-CoV-2 感染的二价结合和抑制作用。
Cell Res. 2021 May;31(5):517-525. doi: 10.1038/s41422-021-00487-9. Epub 2021 Mar 17.
4
Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.从恢复期血浆中生产抗 SARS-CoV-2 超免疫球蛋白。
Transfusion. 2021 Jun;61(6):1705-1709. doi: 10.1111/trf.16378. Epub 2021 Mar 22.
5
Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters.吸入型强效 SARS-CoV-2 中和人源单克隆抗体在仓鼠中的治疗活性。
Cell Rep Med. 2021 Mar 16;2(3):100218. doi: 10.1016/j.xcrm.2021.100218. Epub 2021 Feb 25.
6
Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant.由SARS-CoV-2非D614G变体引发的人类中和抗体对SARS-CoV-2 D614G变体提供交叉保护。
Clin Transl Immunology. 2021 Feb 22;10(2):e1241. doi: 10.1002/cti2.1241. eCollection 2021.
7
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.循环 Sars-CoV-2 刺突 N439K 变体在保持适应性的同时逃避抗体介导的免疫。
Cell. 2021 Mar 4;184(5):1171-1187.e20. doi: 10.1016/j.cell.2021.01.037. Epub 2021 Jan 28.
8
High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.猪源糖基化人源化多克隆抗体对新冠病毒具有高中和效力。
Eur J Immunol. 2021 Jun;51(6):1412-1422. doi: 10.1002/eji.202049072. Epub 2021 Mar 2.
9
SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus.SARS-CoV-2 特异性抗体和中和测定法揭示了针对该病毒的广泛体液免疫反应。
Commun Biol. 2021 Jan 29;4(1):129. doi: 10.1038/s42003-021-01649-6.
10
Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.作为 COVID-19 疗法的抗病毒单克隆抗体面临的挑战与机遇。
Adv Drug Deliv Rev. 2021 Feb;169:100-117. doi: 10.1016/j.addr.2020.12.004. Epub 2020 Dec 9.
Zotero 插件